News Sentiment

ARQT sentiment intelligence

Arcutis Biotherapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 27.74 Week of 10 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+7.5% over one week, +13.8% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Arcutis to report Q2 2026 financial results on August 5

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 7.5% Price confirming higher
Trend fit Trend inactive 13.8% over four weeks
Fair value 96.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 28
Neutral 32
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 11
The Manila Times 4
simplywall.st 4
TradingView 4
Moomoo 4
Stock Traders Daily 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 20
Analyst action 9
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 63
Investing.com Canada Direct company coverage

Arcutis launches virtual dermatology platform for skin conditions By Investing.com

Arcutis Biotherapeutics has launched a virtual health platform connecting patients with board-certified dermatologists for chronic inflammatory skin diseases like eczema and psoriasis. The platform aims to address barriers to in-person care and expand access to diseases for the c

Tone
Positive 71/100
Event
Market update
Published
30 Jun 2026 13:40
Source
Investing.com Canada
The Manila Times Direct company coverage

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

Arcutis Biotherapeutics has launched a new virtual health platform to improve access to care for individuals with chronic inflammatory skin diseases, including those eligible for ZORYVE. The platform connects patients with independent, board-certified dermatologists through a str

Tone
Positive 70/100
Event
Market update
Published
30 Jun 2026 13:40
Source
The Manila Times
Quiver Quantitative Direct company coverage

Arcutis Biotherapeutics Announces FDA Approval of Expanded ZORYVE Cream 0.3% Indication for Children With Plaque Psoriasis Down to Age 2

Arcutis Biotherapeutics announced FDA approval for ZORYVE cream 0.3% to treat plaque psoriasis in children as young as two, marking it as the first once-daily, non-steroidal topical treatment for this age group. This approval addresses a significant treatment gap, offering a safe

Tone
Positive 87/100
Event
Regulatory and legal
Published
29 Jun 2026 22:10
Source
Quiver Quantitative